Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris

NCT05799157 is registered in ClinicalTrials.gov with Veradermics, Inc. as lead sponsor.

NCT NCT05799157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05799157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris
Lead sponsor
Veradermics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2023
Completion date
February 25, 2025
Enrollment
153 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

common wart, verruca vulgaris, warts